Painchek (ASX:PCK) EPS without NRI: A$-0.05 (TTM As of Dec. 2025)


ASX:PCK Painchek Ltd ASX:PCK
52 GF Score
Price A$0.11
GF Value A$0.40
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Painchek EPS without NRI?

Painchek ASX:PCK +8.25% 52 EPS without NRI is A$-0.05 as of Dec. 2025. GuruFocus rates ASX:PCK with a GF Score™ of 52/100 and a GF Value™ of A$0.40 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 511 Healthcare Providers & Services companies, Painchek ranks worse than 61.45% on this metric.

Painchek's earnings per share without non-recurring items for the six months ended in Dec. 2025 was A$-0.02. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.05.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 3.50% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 13.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Painchek's EPS without NRI or its related term are showing as below:

ASX:PCK' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -7.9   Med: 16.8   Max: 41.2
Current: 3.5

During the past 13 years, Painchek's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 41.20% per year. The lowest was -7.90% per year. And the median was 16.80% per year.

ASX:PCK's 3-Year EPS without NRI Growth Rate is ranked worse than
61.45% of 511 companies
in the Healthcare Providers & Services industry
Industry Median: 11.3 vs ASX:PCK: 3.50

Painchek's EPS (Diluted) for the six months ended in Dec. 2025 was A$-0.02. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.05.

Painchek's EPS (Basic) for the six months ended in Dec. 2025 was A$-0.02. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.05.


Painchek  (ASX:PCK) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Painchek EPS without NRI Related Terms


Painchek EPS without NRI Historical Data

* Premium members only.

The historical data trend for Painchek's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Painchek EPS without NRI Chart

Painchek Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.05 -0.05 -0.06 -0.06 -0.04

Painchek Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.03 -0.02 -0.02 -0.02

ASX:PCK vs VEEV, BTSG, TEM: EPS without NRI Comparison

For the Health Information Services subindustry, Painchek's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Painchek PE Ratio without NRI vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Painchek's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Painchek's PE Ratio without NRI falls into.


ASX:PCK
52GF Score
Painchek Ltd ASX:PCK
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Painchek EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of A$-0.05 mean?
Painchek (ASX:PCK) has a EPS without NRI of A$-0.05 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Painchek and its competitors. According to the industry distribution chart, Painchek ranks #314 out of 511 companies in the Healthcare Providers & Services industry, placing it in the top 61.4%.
Is Painchek's EPS without NRI too high?
Painchek's current EPS without NRI is A$-0.05. Based on the distribution chart, Painchek ranks #314 out of 511 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Painchek has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Painchek's EPS without NRI compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Painchek ranks #314 out of 511 companies for EPS without NRI. This places Painchek in the lower half of its industry. The industry median EPS without NRI is 11.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Healthcare Providers & Services company?
The median EPS without NRI among Healthcare Providers & Services companies is 11.30, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Painchek and its competitors. For the Healthcare Providers & Services industry, the median EPS without NRI is 11.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Painchek's current EPS without NRI is A$-0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Painchek stock overvalued right now?
Based on GuruFocus' analysis, Painchek (ASX:PCK) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.40, compared to a current price of A$0.11 — trading 73.8% below its estimated fair value. The current EPS without NRI is A$-0.05. Painchek's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Painchek (ASX:PCK), the current EPS without NRI is A$-0.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Painchek (ASX:PCK) Overvalued in 2026?

Based on GuruFocus' analysis, Painchek stock appears to be undervalued. The current stock price of A$0.11 is trading 73.8% below its estimated GF Value™ of A$0.40. GuruFocus considers Painchek to be Possible Value Trap.

Key valuation signals for ASX:PCK:

  • EPS without NRI: A$-0.05
  • GF Value™: A$0.40 vs. price of A$0.11 (73.8% below fair value)
  • GF Score™: 52/100 with 3 warning signs

No single metric tells the full story. See the ASX:PCK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Painchek Business Description

Address 35 Lime Street, Suite 401, Sydney, NSW, AUS, 2000
Painchek Ltd is engaged in the development and commercialization of mobile medical device applications that provide pain assessment for individuals who are unable to communicate pain with carers. It operates in one segment, namely the sale of its pain assessment solutions. Its geographic segments include Australia, the United Kingdom, and Other countries, of which it generates the majority of its revenue from Australia.
52GF Score

Get the complete analysis for ASX:PCK

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.11
Price
A$0.40
GF Value